The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Alternative Therapies

Alternative Therapies

Alternative Therapies encompass a diverse range of treatments and practices that fall outside the realm of conventional medicine.
This broad category includes complementary, integrative, and holistic approaches, such as herbal remedies, acupuncture, meditation, and other mind-body interventions.
While the efficacy and safety of many alternative therapies are still under investigation, these approaches are increasingly being utilized by patients seeking to supplement or complement traditional medical care.
Researchers exploring alternative therapies can leverage PubCompare.ai, an AI-driven platform that helps optimize research protocols for enhanced reproducibility and accuracy.
By accessing the platform's vast database of literature, preprints, and patents, researchers can identify the most effective alternative therapy approaches and streamline their research process.

Most cited protocols related to «Alternative Therapies»

Predictor variables were those prominent in published research on survey participation and retention, including 7 core demographic variables and 10 physical health variables from either the baseline telephone interview or the SAQ (see Table 1). The demographic variables represented baseline characteristics of age (continuous), gender (0 = male, 1 = female), marital status (0 = not married, 1 = married), race (0 = minority, 1 = White),2 educational level (1 = less than high school, 2 = high school graduate or equivalent, 3 = some college, 4 = college graduate or more), personal income (continuous), and county size (1 = 21 largest MSAs [metropolitan statistical areas], 2 = MSA greater than 85,000 households, 3 = MSA greater than 20,000 households, 4 = remaining counties). Among the health variables included were common measures such as subjective physical health rating (1 = poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent), a count of the number of chronic conditions, a count of functional limitations (instrumental activities of daily living [IADL]), and body mass index (BMI; continuous). Two health behaviors, drinking (0 = ever drink 3+ days/week, 1 = never drank 3+ days/week) and smoking history (1 = currently smoke, 2 = smoked in past, 3 = never smoked), were also included as well as health insurance coverage (1 = no coverage, 2 = government coverage, 3 = private coverage), a count of the number of physician visits in the prior year, and a novel measure of alternative medicine/therapy use (respondents were asked to choose from among 13 listed medicines/therapies used in the prior year: 0 = did not use any in prior year, 1 = used at least one in prior year). The latter was viewed as a possible index of “topic interest” in matters related to a survey about health.
Most sociodemographic variables (except income) were obtained from the baseline phone interview, whereas most health questions (except subjective health, smoking, and drinking behaviors) were obtained from the SAQ. The latter was completed by 87% of the RDD respondents and 92% of the twin and sibling respondents. Thus, the present analysis is limited to those individuals with complete data across the predictors and who participated in both waves of the phone survey. Under these criteria, the sample sizes were as follows—RDD: n = 3,140; Twin: n = 1,520;3 Sibling: n = 745.
Publication 2010
Alternative Therapies Chronic Condition Diagnostic Self Evaluation Gender Households Index, Body Mass Males Minority Groups Pharmaceutical Preparations Pharmacotherapy Physical Examination Physicians Retention (Psychology) Therapeutics Twins Woman
A protocol with explicitly defined objectives, formal consensus development methods, criteria for participant identification and selection, and statistical methods was developed. The study was prospectively registered with the Core Outcome Measures in Effectiveness Trials (COMET) initiative (registration number 603 available online at www.comet-initiative.org/studies/details/603). The ethics board of the Academic Medical Center, Amsterdam, The Netherlands, advised that ethical approval was not required (reference number E2-172) because this project should be considered as service evaluation and development.
The target of the core outcome set was to capture important outcomes for individual studies, systematic reviews, and guidelines for preterm birth prevention in asymptomatic woman. For our purposes, preterm birth was defined as neonates born alive before 37 weeks of gestation.5 (link) An asymptomatic woman was defined as one without symptoms of preterm labor (e.g increased uterine contractions, menstrual cramps of backache, color change of vaginal discharge, prelabor rupture of membranes). Preventive treatment of preterm birth was defined as one started before any symptoms of preterm labor were present. This preventive strategy could be pharmacologic (e.g. progesterone, marine oils, probiotics) or non-pharmacologic (e.g. cerclage, pessary, lifestyle interventions and alternative therapies).
A Project Steering Committee was established to give guidance to the different phases of this project consisting of two obstetricians (Irene de Graaf, Khalid S. Khan), two neonatologists (Timo de Haan, Stephen Kempley), two midwives (Felipe Castro, Birgit van der Goes), two patient representatives (Aoife Ahern, Mandy Daly) and three methodologists with experience in formal consensus and/or core outcome set methods (James Duffy, Brent Opmeer, and Paula Williamson).
A systematic literature review was undertaken searching the Cochrane Pregnancy and Childbirth Group's (PCG) Trials Register.1 The Pregnancy and Childbirth Group register is maintained by monthly searches of the Cochrane Central Register of Controlled Trials and weekly searches of EMBASE and MEDLINE and hand-searches of 30 journal and conference proceedings (from January 1997 to January 2011). The register was searched utilizing the register’s codes for preterm birth. Two reviewers (S.M. and Z.A.) independently screened titles and abstracts. They critically reviewed the full text of selected studies and extracted reported outcomes. Any discrepancies were resolved by discussion. In addition, all delegates (n=168) of the First European Spontaneous Preterm Birth Congress (Svendborg, Denmark, May 24–25, 2014), mainly representing obstetricians and researchers, but also midwives, neonatologists and members of industry, were requested via e-mail to recommend potential outcomes.
Patient representatives and parents were invited through social media (Twitter and patient forums on Facebook) to participate in an online questionnaire to share their opinions regarding outcomes relevant to preterm birth. Members of patient organisations including the European foundation for the Care of Newborn Infants, their partner organizations, and parental forums of neonatal baby units were e-mailed by their own organization including an invitation for the online questionnaire through an electronic newsletter. Patients also contributed their opinions through in-person semistructured interviews conducted by one of the authors (J.v.t.H.).
The Project Steering Committee identified outcomes that were duplicated as a result of varied terminologies used by different stakeholders and for grouping closely related outcomes into overarching domains. This outcome inventory of 29 outcomes was entered into a Delphi process (Figure 1).
We used a two-round electronic Delphi survey design, a well-established method to elicit consensus based on an iterative process with anonymous consultation and with controlled feedback and quantified analysis of the responses.6 A priori we agreed the important methodological features for our Delphi process: [1] composition of the group; [2] anonymity; [3] how to assess the importance of outcomes; [4] method of feedback of results to participants; [5] how consensus would be reached; [6] how to assess possible attrition bias.
The setting for the Delphi survey was multinational involving stakeholders from middle- and high-income countries. A formal written invitation was e-mailed to all members of the Cochrane Pregnancy and Childbirth group (n=30), the Core Outcomes in Women’s Health initiative (n=77), the European Preterm Birth Congress (n=168), and the Global Obstetrics Network (n=237). Most members of these organizations are researchers (methodologists), obstetricians (mainly specialized in maternal fetal medicine) or neonatologists. The European foundation for the Care of Newborn Infants approached their members themselves, including their partner organizations in Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Mexico, the Netherlands, Norway, Poland, Portugal, Spain, Turkey, United Kingdom, and the United States. All midwifes from ‘Barts Health Nursing and Midwifery’ (n=132) and some midwifes of the School of Nursing and Midwifery (Galway, Ireland) and the Dutch Consortium for Healthcare Evaluation in Obstetrics and Gynaecology were approached. With this approach we aimed to targeted midwifes who were active in research (50%) and midwifes who were not active in research (50%). In total 337 obstetricians, 152 midwives, 174 researchers, 75 neonatologists, and an unknown number of parents (through the previously mentioned patient organizations) were invited.
We used LimeSurvey for the Delphi survey. The survey was piloted first by eight people representing every stakeholder group. No changes were needed after the pilot. The official survey had a closing date of 5 weeks after the date of invitation for every Delphi round. An e-mail reminder was sent to participants on days 7, 14, 21, and 28. Nonresponders in the first round were not invited to participate in the subsequent round.
Participants were asked to rate the importance of each outcome on a 9-point Likert scale anchored between 1 (‘limited importance’) and 9 (‘critical importance’). The scale is recommended by the Grading of Recommendations Assessment, Development and Evaluation working group: 1–3: limited importance; 4–6: important but not critical; 7–9: critical.7 (link) Participants were invited to recommend additional potential outcomes for consideration at the end of the survey using free-text responses.
The individual, stakeholder group and total results from the first round were relayed back to participants by e-mail; the individual responses directly after filling in the first round questionnaire, the stakeholder group, and total group responses were fed back anonymously 1 day prior to the invitation to the second round of the Delphi survey. Furthermore, participants of the second survey were able to see the mean value of the total group responses from the first Delphi round while completing the survey. Participants were asked to score all the individual outcomes again using the same 9-point Likert scale. No outcomes were excluded in this round to ensure a holistic approach to scoring in round 2.
The Delphi survey responses were analyzed using SPSS version 21.0. For each outcome the median and interquartile range were calculated. Frequency tables of all scores were generated, as well as boxplots for visualization (that were used to relay back the whole and stakeholder group responses). We defined consensus a priori. Core outcomes required at least 70% of participants in each stakeholder group scoring the outcome as ‘critical’ and less than 15% of participants in each stakeholder group scoring the outcome as ‘limited importance’.8 (link) Outcomes which should not be included in a core outcome set required at least 70% of participants in each stakeholder group scoring the outcome as ‘limited importance’ and less than 15% of participants in each stakeholder group scoring the outcome as ‘critical’. If outcomes did not meet either criteria they were classified as outcomes with no consensus. Attrition bias (e.g. a selective group did not respond to the second round of the survey or a selective group participated in the consultation meeting) was assessed by 1) comparing the distribution of median first round scores across the outcomes for those not participating in the second round with those who did; and 2) comparing the distribution of median round 2 scores across the outcomes for those participating in the consultation meeting compared with those who did not.
The final phase of the study was a face-to-face consultation meeting with participants of the Delphi exercise representing all stakeholder groups (Washington, DC, November 9, 2014). This meeting was organized within a meeting for a prospective individual participant data analysis project for studies on the use of pessary in the prevention of preterm birth in asymptomatic women. Eleven participants of this prospective individual patient data project did also took part in the Delphi survey earlier. They mainly represented the stakeholder groups of obstetricians and methodologists. Representatives from the other stakeholder groups (parents, midwives and neonatologists), who were living close to the location of the consultation meeting, were invited for this consultation meeting as well. In total 23 obstetricians, 10 researchers, two neonatologists, two patient representatives, and one midwife were invited to attend this meeting. Information material on the purpose of the consultation meeting and the Delphi round 2 results were sent to participants before the meeting. A plenary presentation on the Delphi survey outcomes was complemented by small group sessions (mixed groups) where participants expressed their views on the candidate outcomes. Only outcomes that did not reach full consensus in the Delphi exercise were presented to the attendees of the meeting with an anonymous voting using electronic touchpads. Consensus in the consultation meeting required a majority of 70% of participants from each stakeholder group approving an individual outcome as ‘critical’ according to the 1–9 Likert scale. With the permission of the participants the consultation meeting was recorded.
Publication 2016
Alternative Therapies Back Pain Childbirth Comet Assay Dysmenorrhea Europeans Face Fetal Membranes, Premature Rupture Genetic Code Infant Infant, Newborn Marines Midwife Neonatologists Obstetrician Oils Parent Patient Representatives Patients Pessaries Pregnancy Premature Birth Premature Obstetric Labor Probiotics Progesterone Tooth Attrition Uterine Contraction Woman
CIMT is a well-known intervention that combines behavioral and physical training by requiring a patient to use the impaired limb when the less affected limb is immobilized, usually by placing the less affected hand in a mitt that prevents opposition and grasp or, alternatively, by placing the entire UE in a sling. In the EXCITE trial, participants were randomly assigned to either the immediate (3–9 months poststroke) or delayed (over 1 year later) groups. Approximately half of those participants randomized to the delayed group received traditional physical therapy or alternative therapy treatments not associated with the EXCITE trial.5 (link),13 (link) During the training period, all participants donned a safety mitt on their less impaired UE for 90% of their waking hours for 14 consecutive days. On weekdays (10 days), they received adaptive task practice (ATP) and repetitive task practice (RTP) progressing up to 6 hours. ATP is a form of behavioral training, also referred to as “shaping,” while RTP is less structured emphasizing repetition of common tasks such as eating or grooming for typical intervals of 15 to 20 minutes.5 (link)
Publication 2009
Acclimatization Alternative Therapies Grasp Menstruation Disturbances Patients Safety Therapy, Physical
Our goal was to summarize and compare implementation experiences of early adopters of CYP2C19 pharmacogenomic testing to guide antiplatelet medication selection. The study population included 12 large academic institutions within the IGNITE Network Pharmacogenetics Working Group (five funded institutions and seven affiliate members)1 (link) who have tested 6340 patients for CYP2C19 alleles (see Table S1 for a breakdown by site).
Data collection was completed at each site through a structured electronic spreadsheet disseminated to each site leader. Specific data elements were selected and definitions were refined through open discussions at several in-person meetings and conference calls from September 2016 to May 2017. The tool was then pilot-tested for feasibility prior to dissemination to all sites. Areas of focus included the baseline genetics testing landscape at each site, stakeholder involvement, the design of each implementation program, testing approaches, informatics setup, return of results procedures, and any education provided. Eight of the 12 sites also provided data on antiplatelet medication use after genotyping (1858 total patients). Data cleaning was accomplished iteratively through direct follow-up communications. All data elements collected were reported.
Program performance metrics including testing turnaround times, reported predicted phenotype frequencies, and drug prescribing patterns were also sought from local EHRs or research study data sources when available. All data abstraction and reporting was approved by local institutional review board at each site. Descriptive statistics were reported by institution and proportions of patients with specific test results prescribed alternative therapy were compared using chi square testing. Finally, common challenges that must be overcome and recommendations (lessons learned) for those considering similar implementations in the future were solicited from site investigators and aggregated to a consensus lists through multiple rounds of telephone conference call discussions.
Publication 2018
Alleles Alternative Therapies Antiplatelet Agents Catabolism Conferences CYP2C19 protein, human Ethics Committees, Research Patients Phenotype
After the TFP meeting was complete, recommendations were derived from directly transcribing final clinical scenario ratings. Based on the ratings, scenario permutations were collapsed to yield the most parsimonious recommendations. For example, when ratings favored a drug indication for both moderate and high disease activity, one recommendation was given, specifying “moderate or high disease activity.” In most circumstances, the recommendations included only positive and not negative statements. For example, the recommendations focused on when to initiate specific therapies rather than when an alternate therapy should not be used. Most of the recommendations were formulated by drug category (DMARD, anti-TNF biologic, non-TNF biologic listed alphabetically within category), since in many instances, the ratings were similar for medications within a drug category. We specifically note instances where a particular medication was recommended but others in its group were not endorsed. Two additional community-based rheumatologists (Drs. Anthony Turkiewicz and Gary Feldman) independently reviewed the manuscript and provided comments. CEP and TFP members reviewed and approved all final recommendations.
For each final recommendation, the strength of evidence was assigned using the methods from the American College of Cardiology (11 (link)). Three levels of evidence are specified: 1) Level of Evidence A: data were derived from multiple randomized clinical trials (RCTs) ; 2) Level of Evidence B: data were derived from a single randomized trial or nonrandomized studies; 3) Level of Evidence C: data were derived from consensus opinion of experts, case studies, or standards of care. The evidence was rated by four panel experts (J.O. and J.K.; A.K. and L.M.—each rated half the evidence), and discrepancies were resolved by consensus.
Level C evidence often denoted a circumstance where medical literature addressed the general topic under discussion but it did not address the specific clinical situations or scenarios reviewed by the panel. Since several (but not all) recommendations had multiple components (in most cases multiple medication options), a range is sometimes provided for the level of evidence ; for others, the level of evidence is provided following each recommendation.
Publication 2012
Alternative Therapies Antirheumatic Drugs, Disease-Modifying Biopharmaceuticals Cardiovascular System Pharmaceutical Preparations Rheumatologist

Most recents protocols related to «Alternative Therapies»

This study is a prospective, exploratory, observational trial involving the collection of blood samples from patients with unresectable stage III NSCLC. We enrolled patients with histologically or cytologically confirmed NSCLC who received CCRT at Chonnam National University Hwasun Hospital between March 2020 and March 2021. Patients who completed planned CCRT and had not progressed following the treatment were administered DC. The completion of CCRT was defined as the inclusion criteria of the PACIFIC trial [2 (link)], that is, patients had received platinum-based chemotherapy concurrently with RT at a total dose of at least 60 Gy (54 to 66 Gy). Patients who underwent radical surgery before CCRT were excluded.
The first follow-up chest CT scan after CCRT was performed within six weeks after the last date of RT and was repeated every 8 to 12 weeks after that. In the DC group, after the completion of CCRT, durvalumab (10 mg/kg) was administered intravenously for 60 min every two weeks and continued for a maximum duration of 12 months until confirmed progression, initiation of alternative cancer therapy, unacceptable toxicity, or the occurrence of other reasons to discontinue the drug. A follow-up chest CT scan was performed after every four to six cycles of durvalumab. The clinical response to the treatment was defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [12 (link)].
Full text: Click here
Publication 2023
Alternative Therapies Chest Disease Progression durvalumab Malignant Neoplasms Non-Small Cell Lung Carcinoma Operative Surgical Procedures Patients Pharmaceutical Preparations Pharmacotherapy Platinum Specimen Collections, Blood X-Ray Computed Tomography

This was a single-center randomized controlled trial performed at the endoscopy unit of Mansoura Specialized Medical Hospital, Mansoura University, Egypt, between February 2019 and February 2022. The Study population included 52 patients with high-risk GVs classified according to the Sarin and Kumar classification
3 (link)
into GOV2 or IGV1. The inclusion criteria were as follows: age > 18 years, primary prophylaxis for high risk GVs varices (> 20 mm) on initial standard diagnostic upper endoscopy, and patients unable or unwilling to undergo alternative therapies for GVs such as transjugular intrahepatic portosystemic shunts (TIPS) or surgery. Patients were excluded if unable to give informed consent for the procedure, concurrent hepatorenal syndrome and/or multiorgan failure, previous endoscopic treatment for GVs, hepatocellular carcinoma or portal and splenic vein thrombosis, esophageal stricture, pregnant, platelets count less than 50,000 /mL and International Normalized Rate (INR) > 2.
Eligible patients were randomized in two groups using computer-generated random number sequences using excel software in concealed envelopes with block randomization design. Group A underwent EUS-guided injection of 1 ml CYA into the perforator vein and Group B underwent DEI of 1 mL CYA into the varix. Informed written consent was obtained from each participant in the study after assuring confidentiality. The study protocol and consent form were approved by the Institutional Review Board of Mansoura faculty of medicine, Mansoura University. The study was conducted in accordance with the Declaration of Helsinki and registered at ClinicalTrials.gov under the code NCT04222127.
Publication 2023
Alternative Therapies Blood Platelets Diagnosis Endoscopy Endoscopy, Gastrointestinal Esophageal Stricture Ethics Committees, Research Faculty Hepatocellular Carcinomas Hepatorenal Syndrome Multiple Organ Failure Operative Surgical Procedures Patients Pharmaceutical Preparations Primary Prevention Sarin Shunt, Transjugular Intrahepatic Portosystemic Spleen Thrombosis Varices Veins Veins, Splenic Venous Thrombosis
Recruitment consecutively took place in the tetraparesis department of the KMT as a sample of convenience. Due to the availability of the HAL the recruitment was performed from May 2021 to December 2021. The inclusion and exclusion criteria were based on existing literature and the mechanical properties of the HAL. Table 1 gives an overview of the inclusion and exclusion criteria of the study. All participants were recruited from the patient population from the clinic. Blinding of the therapist or participants due to the kind of intervention was not possible. The data were analysed anonymously.

Inclusion and exclusion criteria

Inclusion criteriaExclusion criteria
• Spastic Cerebral Palsy• Lower limb surgery in the past 6 months
• Age over 18 years• Botulinum toxin therapy in the past 3 months
• GMFCS III + II• Use of alternative RAGT in the past 6 months
• 14 m walking ability• Current fractures or skin lesions
• Adequate pain reporting (CFCS level I – III)• Impaired peripheral blood supply
• Ability to follow instructions (CFCS level I – III)• Inability to follow instructions
• Written informed consent• Height under 150 cm and over 170 cm

GMFCS: Gross Motor Functions Classification System; RAGT: Robot−assisted gait training; CFCS: Communication Function Classification System

Full text: Click here
Publication 2023
Alternative Therapies Botulinum Toxins Cardio-Facio-Cutaneous Syndrome Fracture, Bone Lower Extremity Operative Surgical Procedures Pain Patients Quadriparesis Skin Spastic Cerebral Palsy
In this study, the outcomes of surgical procedures were monitored only during in-hospital treatment. Outcomes were recorded with respect to the rate of post-operative complications (mortality, early reoperation, cerebrovascular insult, pacemaker implantation, atrial fibrillation, AV block, systemic inflammatory response syndrome (SIRS), wound infection) and hospital cost.
For pharmacoeconomic analysis, the total hospital costs for each operated patient served as the initial parameter. The effectiveness of the procedure was assessed by the percent of patients who had no complications. Incremental effectiveness was calculated as the difference in the effectiveness between the given groups. The results of the pharmacoeconomic analysis were presented as the cost-effectiveness ratio (CER) and incremental cost-effectiveness ratio (ICER). CER is calculated as the ratio of the cost of each individual therapy (procedure) and its therapeutic effect. ICER is calculated as the ratio of the cost difference of two alternative therapies and the difference in effectiveness between the compared therapies. ICER, in fact, shows the additional costs per unit of additional effectiveness. Outcomes were analyzed separately according to the surgical technique as well as by the type of valve used.
CER=Cost of each individual procedure (EUR)Therapeutic Effect 
ICER=Cost difference (EUR)Difference in Outcome 
Full text: Click here
Publication 2023
Alternative Therapies Atrial Fibrillation Atrioventricular Block Hospital Administration Inpatient Operative Surgical Procedures Ovum Implantation Pacemaker, Artificial Cardiac Patients Postoperative Complications Second Look Surgery Systemic Inflammatory Response Syndrome Therapeutic Effect Therapeutics Wound Infection
All women affected by EMPD of the vulva and attending the Preventive Gynecologic Unit of the European Institute of Oncology, Milan, Italy, from October 1997 to May 2020, were retrieved from hospital file archives and enrolled in a retrospective analysis.
The local Institutional Review Board approved the study protocol (IEO protocol number UID 2408, date of approval: 22 June 2020) and written informed consent for the use of data for scientific purposes was obtained from all subjects prior to treatment.
Patients were included if the following criteria were met: (a) age at diagnosis of 18 years or older; (b) histologic confirmation of vulvar EMPD; (c) available data regarding follow-up. Patients were excluded in the case of different histology of vulvar neoplasia.
The data regarding clinical and pathological characteristics of the patients were recorded in a dedicated database.
The histological characteristics of first diagnosis, vulvar recurrence and cervical and/or vaginal localization were retrieved from surgical and pathological reports. All histological diagnoses were conducted by dedicated gynecological pathologists working at the Pathology Division of our Institute. Vulvar EMPD was classified according to the classification of Wilkinson and Brown as either primary, if Paget cells were of cutaneous origin, or secondary, in the case of vulvar skin involvement derived from an internal noncutaneous malignancy. The primary vulvar EMPD was further classified as exclusively intraepithelial (Type 1a), associated with stromal invasion (Type 1b) and as a manifestation of a primary vulvar adenocarcinoma (Type 1c). Secondary vulvar EMPD could be associated with anal or rectal adenocarcinoma (Type 2a), urothelial carcinoma (Type 2b) and distant tumors, including hepatocellular and breast carcinomas (Type 2c) [7 (link)].
Follow-up was routinely scheduled at the dedicated Vulvar Pathology Clinic of our Institute.
Apart from primary HPV screening, a pap smear was routinely performed once a year, also in women older than 65 years. In the case of abnormal cytology, women underwent colposcopy with cervical and/or vaginal guided biopsies. When atypical glandular cells were detected, endocervical curettage, endometrial biopsy and transvaginal ultrasound were always performed to rule out the origin of abnormal cells from endocervix, endometrium, ovary or Fallopian tube. If not available, HPV testing was conducted to exclude HPV-related disease.
A dedicated database was prospectively filled at each follow-up visit.
Therapeutic approaches, including surgery and alternative treatments such as topical therapy with imiquimod, photodynamic therapy and radiotherapy, as well as the type and timing of any persistence or recurrence, invasive disease and cervico-vaginal (CV) localization of EMPD were registered.
To improve the accuracy of the survival data, telephone interviews and consultation of civil registries were allowed in the case of patients lost to follow-up.
Full text: Click here
Publication 2023
Adenocarcinoma Administration, Topical Alternative Therapies Anus Biopsy Breast Carcinoma Carcinoma, Transitional Cell Cells Childbirth Colposcopy Curettage Cytological Techniques Diagnosis Endocervix Endometrium Ethics Committees, Research Europeans Fallopian Tubes Germ Cells Imiquimod Malignant Neoplasms Neck Neoplasms Operative Surgical Procedures Ovary Pathologists Patients Photochemotherapy Radiotherapy Rectum Recurrence Skin Therapeutics Ultrasonics Vagina Vaginal Smears Vulva Vulvar Neoplasms Woman

Top products related to «Alternative Therapies»

Sourced in Canada
The Trevo Proview is a compact and versatile lab equipment designed for various applications. It provides a reliable and efficient solution for tasks requiring precise temperature control and monitoring. The core function of the Trevo Proview is to maintain and regulate temperature with accuracy and consistency.
Sourced in United States, Denmark, United Kingdom, Canada, Austria
Stata 11 is a comprehensive statistical software package developed by StataCorp. It provides a wide range of data management, analysis, and visualization tools for researchers, students, and professionals across various fields. Stata 11 offers a flexible and user-friendly interface to handle complex data, perform advanced statistical analyses, and generate high-quality reports and graphics.
Sourced in United States, Cameroon, Austria
SAS statistical software version 9.4 is a comprehensive suite of data analysis tools. It provides a wide range of statistical and analytical capabilities to support data management, visualization, and modeling. The software offers advanced techniques for data processing, modeling, and reporting, catering to the needs of researchers, analysts, and organizations across diverse industries.
Sourced in United States, United Kingdom, Austria, Denmark
Stata 15 is a comprehensive, integrated statistical software package that provides a wide range of tools for data analysis, management, and visualization. It is designed to facilitate efficient and effective statistical analysis, catering to the needs of researchers, analysts, and professionals across various fields.
Sourced in United States, Germany, United Kingdom, Belgium, Japan, China, Austria, Denmark
SPSS v20 is a statistical software package developed by IBM. It provides data management, analysis, and visualization capabilities. The core function of SPSS v20 is to enable users to perform a variety of statistical analyses on data, including regression, correlation, and hypothesis testing.
Sourced in United States, Austria, Japan, Cameroon
SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United Kingdom
Durvalumab is a monoclonal antibody used in research laboratory settings. It primarily functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death-ligand 1 (PD-L1) protein. This product is intended for use in various research and scientific applications.

More about "Alternative Therapies"

Complementary and Alternative Therapies (CAT) encompass a diverse range of treatments, practices, and approaches that fall outside the realm of conventional allopathic medicine.
This broad category includes complementary, integrative, holistic, and natural health methods, such as herbal remedies, acupuncture, meditation, mind-body interventions, and other non-traditional practices.
While the efficacy and safety of many CAT modalities are still under investigation, these approaches are increasingly being utilized by patients seeking to supplement or complement their traditional medical care.
Researchers exploring CAT can leverage AI-driven platforms like PubCompare.ai to optimize their research protocols for enhanced reproducibility and accuracy.
By accessing PubCompare.ai's vast database of literature, preprints, and patents, researchers can identify the most effective CAT approaches and streamline their research process.
The platform's AI-driven comparisons help researchers pinpoint the best protocols and products, unlocking new insights and enabling more efficient and impactful studies.
Researchers can also explore related statistical software like Stata, SAS, and SPSS to analyze their CAT research data, as well as tools like Prism for data visualization and Trevo Proview for literature review.
By combining these advanced resources, researchers can gain a more comprehensive understanding of the CAT landscape and advance the scientific understanding of these alternative therapies.